London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dr Hitesh Mistry is currently named in that position, has he finally parted ways with Physiomics?
Doesn’t seem much confidence with a positive result tomorrow.
Meanwhile, new post being advertised “Principle Consultant”.
https://uk.linkedin.com/jobs/view/principal-consultant-head-of-modelling-at-physiomics-plc-3848190072
I was aware that he has other non-executive directorships which he openly admits take up very little of his time
The position at Karganera is as an executive one, unlike that at PYC
Right across AIM shares,of all market capitalisation volume has been the lowest for years according to some .
Certainly I have noticed a marked change in the last 12mths ,
As for JM he has always had several other roles and is "fully committed " according to the Q and A
Usually PYC state if they at attending I think ?
Who knows Trench.
I think a question like this has been asked before in previous IM, where Millen said he was a member of other boards, but that it took nothing away from his time at PYC?
You would have thought with interims due on Thursday, that there would be more volume, but hardly anything.
Bicycle are attending AACR2024, i wonder if Physiomics will be?
Https://www.kargenera.com
Jim Millen is a Director here. Has he been fully focused on PYC in recent months ?
The £137k grant covers the two-year study through to October 2025. Income will be credited to each accounting period on a pro-rata basis depending on the work completed in that period. It is likely that the initial scoping out work would have started before 31st December 2023 but I would expect that the amount to be credited for this work would be relatively small
Hence Physiomics will receive £137,376 over the course of the Project which will start immediately
I do not believe there will be much grant income in the half year to 31st December 2023. Time spent on the new Blackpool Victoria Hospital study would be minimal by that date and the old Portsmouth Hospital work was complete by early 2023
Maybe I am missing something ?
They are reporting on the half year which are a) known b) under Jim
When Peter did the presentations recently they've had every opportunity to state whether they are no longer targeting the "best ever income of £1mln" for full year June 2023/24 so one would hope Peter wouldn't be foolish enough to over promise
Looking at the income and contracts H1 it looks like about £350-400k H1 (£125k + £130k grant income + 3 or 4 other contracts)
Does Peter have a "free hit" here, if they are disappointing ( possibly ) it could be said that the numbers are down to Jim, or too many intangibles for this?
They also tweeted about Project Optimus yesterday ( the same tweet has been sent out before ) but they did not put #PYC after it.
They on;y put the hashtag on a follow on tweet which also had a spelling mistake. Not very professional.
I think this is automatic info sent out by the Investors meet company platform... to do these types of calls / presentations presumably they will have to book a slot and pay for this service
I note there is inconsistencies within the RNS - the last two are very different in the "About Physiomics Jazz" at the bottom.
I also note that why has the latest RNS got a "Question Mark ? " after virtual Tumour and CRUK has been droppped?
if this is merely a mistake then the attention to detail !!!!
RNS 1st March 2024
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour? technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
RNS 19th February 2024
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
Strange, not sure if PYC has did this in the past when Interims posted.
https://x.com/InvestorMeetCo/status/1763589672016449891?s=20
Thursday 7th March for half year ended Dec 2023
I posted this early January :
A PYC tweet issued last week included 'We can’t wait to share with you all the exciting developments we have planned for the year ahead'. Interestingly, Valirx issued a similarly worded tweet including 'we're looking forward to showing you what we have planned for an exciting year ahead'
Probably coincidence or perhaps they use the same script writer. Could it be there is some form of closer working relationship between the two planned ?
I note that there have been no exciting developments this calendar year on either PYC or VAL. Clarification will be needed on the tweet at Physiomics IMC presentation later this month if nothing substantial announced by then
Interims will be next week I think.
This week we had following low trades.
Mon 61
Tue 31
Wed 33
Thur 33
Fri. 33
Next week maybe RNS for Interims, will this have an effect on SP?
Will there be another RNS?
Going wild another 33 lol
Someone is building a sizable chunk here with all these trades.... :-)
Needs to be questioned….
BOD of directors all used to work for the same company.
Val Lab PYC has an agreement with
Scientific Advisory Board Together.
All seems like they getting tighter…. VAL has been decimated (so have we mind) but doesn't give a good vibe
KingH I totally agree with your sentiment
Was Global Senior Vice President and Head of Capital Solutions for Syneos Health
Syneos is where Dr Peter Sagenent and Dr Kumar used to work….
The relationship seems to be getting closer which I’m
Not sure is a good thing….
PYC needs to stay away from Val in my eyes……
2 little thingies ... 33